^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    tarextumab (OMP-59R5)

    i
    Other names: OMP-59R5, anti-Notch 2/3 monoclonal antibody, TRXT
    Company:
    Mereo Biopharma, Novartis
    Drug class:
    Notch-2 receptor inhibitor, Notch-3 receptor inhibitor
    6years
    EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumour-Initiating Cell Frequency. (PubMed, Clin Cancer Res)
    These findings suggest that the co-blockade of EGFR and Notch signalling has the potential to increase the response to PI3K inhibition and PTG12 may gain clinical efficacy when combined with PI3K blockage in cancer treatment.
    Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    pictilisib (GDC-0941) • tarextumab (OMP-59R5)
    over6years
    A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. (PubMed, Invest New Drugs)
    Inhibition of Notch pathway signaling was demonstrated at these doses. ClinicalTrials.gov Identifier: NCT01277146.
    Clinical • P1 data • Journal
    |
    NOTCH2 (Notch 2)
    |
    tarextumab (OMP-59R5)